A recent study from the Yale Comprehensive Cancer Center, Yale School of Medicine, Cedar Street, New Haven, Connecticut, USA; Dana-Farber/Brigham and Women’s Cancer Center, Brookline Avenue, Boston, Massachusetts, USA; and others shows that “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.” This study was published in the 27 November 2014 issue of Nature (the number 1 journal in Science with an impact factor of 42) by Prof Hodi FS, Herbst RS and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based cancer immunotherapy: 6-Gingerol, a pungent component of Ginger, decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., Natural product-based cancer immunotherapy: 6-Gingerol, a pungent component of Ginger, decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene, 18/May/2015, 12.34 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year.
The study presented here suggests that 6-Gingerol, by decreasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may activate the immune system and inhibit metastatic progression. Thus, pharmacological formulations encompassing “6-Gingerol or its analogues“ may be used to inhibit the progression of tumors.
Undisclosed information: How 6-Gingerol suppresses the expression of PD-1
Courtesy: When you cite drop us a line at email@example.com